Literature DB >> 7531735

The benzodiazepines as adjuvant analgesics.

S Reddy1, R B Patt.   

Abstract

There has been long-standing debate regarding whether benzodiazepines possess analgesic properties that are independent of their effects on mood and alertness. A careful review of the literature reveals insufficient evidence to support the contention that the benzodiazepines have meaningful analgesic properties in most clinical circumstances. Treatment with the benzodiazepines may reduce complaints of pain, but this seems to be an indirect effect related to their psychotropic properties, such as alleviation of anxiety and, in selected cases, depression. In the absence of definitive data, clinical experience suggests a potential role for treatment with benzodiazepines for acute muscle spasm, concomitant chronic pain and anxiety, and lancinating neropathic pain, in which case clonazepam and alprazolam may be the agents of choice. They should probably not be considered as first-line choices even for the above indications, since potential benefits must be considered in the context of potential for the development of cognitive impairment, physical and psychological dependence, worsening depression, overdose, and other side effects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7531735     DOI: 10.1016/0885-3924(94)90112-0

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  11 in total

Review 1.  [Drug therapy of back pain].

Authors:  M A Rauschmann; D von Stechow
Journal:  Orthopade       Date:  2003-12       Impact factor: 1.087

Review 2.  Pain Management in Pediatric Chronic Kidney Disease.

Authors:  Amanda Reis; Caitlyn Luecke; Thomas Keefe Davis; Aadil Kakajiwala
Journal:  J Pediatr Pharmacol Ther       Date:  2018 May-Jun

3.  Association between chiropractic spinal manipulative therapy and benzodiazepine prescription in patients with radicular low back pain: a retrospective cohort study using real-world data from the USA.

Authors:  Robert James Trager; Zachary A Cupler; Kayla J DeLano; Jaime A Perez; Jeffery A Dusek
Journal:  BMJ Open       Date:  2022-06-13       Impact factor: 3.006

Review 4.  Cancer pain and anxiety.

Authors:  Paul D Thielking
Journal:  Curr Pain Headache Rep       Date:  2003-08

5.  Using Analgesics for Emotional Modulation is Associated With Increased Distress, Depression, and Risk of Opioid and Alcohol Misuse: Initial Evaluation and Component Analysis of the Reasons for Analgesic Use Measure (RAUM).

Authors:  Kevin E Vowles; Robert W Bailey; Mindy L McEntee; Melissa Pielech; Karlyn A Edwards; Lena A Bolling; W Evan Rivers
Journal:  Clin J Pain       Date:  2018-10       Impact factor: 3.442

6.  Co-prescription of opioids with benzodiazepine and other co-medications among opioid users: differential in opioid doses.

Authors:  Che Suraya Zin; Fadhilah Ismail
Journal:  J Pain Res       Date:  2017-01-25       Impact factor: 3.133

7.  Trigeminal Nerve Transection-Induced Neuroplastic Changes in the Somatosensory and Insular Cortices in a Rat Ectopic Pain Model.

Authors:  Satoshi Fujita; Kiyofumi Yamamoto; Masayuki Kobayashi
Journal:  eNeuro       Date:  2019-01-28

8.  In Vivo Antinociceptive, Muscle Relaxant, Sedative, and Molecular Docking Studies of Peshawaraquinone Isolated from Fernandoa adenophylla (Wall. ex G. Don) Steenis.

Authors:  Fahad A Alhumaydhi; Abdullah S M Aljohani; Umer Rashid; Zafar Ali Shah; Abdur Rauf; Naveed Muhammad; Yahya S Al-Awthan; Omar Salem Bahattab
Journal:  ACS Omega       Date:  2021-01-04

9.  Metal-bio functionalized bismuthmagnetite [Fe3-x Bi x O4/SiO2@l-ArgEt3 +I-/Zn(ii)]: a novel bionanocomposite for the synthesis of 1,2,4,5-tetrahydro-2,4-dioxobenzo[b][1,4]diazepine malononitriles and malonamides at room temperature and under sonication.

Authors:  Fatemeh Molaei Yielzoleh; Kobra Nikoofar
Journal:  RSC Adv       Date:  2022-04-01       Impact factor: 3.361

Review 10.  Limited Utility for Benzodiazepines in Chronic Pain Management: A Narrative Review.

Authors:  Steven L Wright
Journal:  Adv Ther       Date:  2020-05-06       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.